LLY
NYSEELI LILLY & Co
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$28.3B
2021
$28.5B
2022
$34.1B
2023
$45.0B
2024
$65.2B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$65.2B
Net Income$20.6B
Gross Profit—
Oper Income—
EPS (dil)$22.95
Rev/sh$69.21
FCF/sh—
Book/sh$28.18
Gross M—
Oper M—
Profit M31.7%
FCF M—
ROE77.8%
ROA18.4%
ROIC—
R&D/Rev11.0%
Rev Y/Y44.7%
Rev 3Y CAGR31.7%
EPS Y/Y96.0%
EPS 3Y CAGR49.3%
FCF 3Y CAGR—
Payout26%
Div/sh$6.23
Shs Chg Y/Y-0.5%
Current Ratio1.58
Quick Ratio1.19
Debt/Eq1.60
Int Coverage—
Net Debt$35.2B
Total Debt$42.5B
Cash & Eq$7.3B
Total Assets$112.5B
Oper CF$16.8B
Capex—
Free CF—
Buybacks$4.1B
Equity$26.5B
Liabilities—
Shs Outstand0.94B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $28.3B | $28.5B | $34.1B | $45.0B | $65.2B |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | $5.6B | $6.2B | $5.2B | $10.6B | $20.6B |
| Diluted EPS | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 |
| Operating Cash Flow | $7.4B | $7.6B | $4.2B | $8.8B | $16.8B |
| Free Cash Flow | — | — | — | — | — |
COMMUNITY · $LLY0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.